Bartomeu Massutí

机构：Hospital General Universitario de Alicante Doctor Balmis · ORCID：0000-0002-6247-4493

发表论文 433 篇 · 总被引 21045 次 · h-index 57

代表论文

• Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial (2024 · The Lancet Oncology · 被引 91)
• Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial. (2024 · Journal of Clinical Oncology · 被引 19)
• BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial. (2024 · Journal of Clinical Oncology · 被引 13)
• Adjuvant Durvalumab in Completely Resected Early-Stage Non–Small Cell Lung Cancer (2026 · Journal of Clinical Oncology · 被引 12)
• Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial) (2025 · OncoImmunology · 被引 9)
• Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non–Small Cell Lung Cancer (2026 · Clinical Cancer Research · 被引 8)